S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Veru Stock Forecast, Price & News

0.00 (0.00%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.01 million shs
Average Volume
2.09 million shs
Market Capitalization
$471.38 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

Veru logo

About Veru

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm's breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects; and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and fin


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Personal Products
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$61.26 million
Book Value
$1.91 per share


Net Income
$7.39 million
Pretax Margin




Free Float
Market Cap
$471.38 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.99 out of 5 stars

Medical Sector

615th out of 1,405 stocks

Pharmaceutical Preparations Industry

293rd out of 678 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Veru (NASDAQ:VERU) Frequently Asked Questions

Is Veru a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Veru stock.
View analyst ratings for Veru
or view top-rated stocks.

How has Veru's stock been impacted by Coronavirus (COVID-19)?

Veru's stock was trading at $3.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VERU stock has increased by 84.1% and is now trading at $5.89.
View which stocks have been most impacted by COVID-19

Are investors shorting Veru?

Veru saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 1,960,000 shares, a decrease of 26.3% from the December 15th total of 2,660,000 shares. Based on an average daily trading volume, of 964,400 shares, the days-to-cover ratio is currently 2.0 days. Currently, 3.1% of the company's shares are short sold.
View Veru's Short Interest

When is Veru's next earnings date?

Veru is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Veru

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) issued its quarterly earnings results on Thursday, December, 2nd. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.04. Veru had a net margin of 12.07% and a negative trailing twelve-month return on equity of 8.61%. During the same period in the previous year, the firm earned ($0.01) EPS.
View Veru's earnings history

What price target have analysts set for VERU?

4 brokers have issued 12-month price objectives for Veru's stock. Their forecasts range from $19.00 to $26.00. On average, they anticipate Veru's stock price to reach $22.00 in the next year. This suggests a possible upside of 273.5% from the stock's current price.
View analysts' price targets for Veru
or view top-rated stocks among Wall Street analysts.

Who are Veru's key executives?

Veru's management team includes the following people:
  • Mitchell Shuster Steiner, Chairman, President & Chief Executive Officer
  • Michele Greco, Chief Financial & Administrative Officer
  • Robert H. Getzenberg, Executive Vice President-Medical Affairs
  • Domingo Rodriguez, Executive Vice President-Clinical Operations
  • K. Gary Barnette, Chief Scientific Officer

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), OrganiGram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $5.89.

How much money does Veru make?

Veru has a market capitalization of $471.38 million and generates $61.26 million in revenue each year. The company earns $7.39 million in net income (profit) each year or $0.11 on an earnings per share basis.

How many employees does Veru have?

Veru employs 339 workers across the globe.

What is Veru's official website?

The official website for Veru is www.veruhealthcare.com.

Where are Veru's headquarters?

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at (305) 509-6897, via email at [email protected], or via fax at 312-595-9122.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.